Evidence map›Paper›PMID 36128323›Full record

ArticleJournal of clinical virology plus2022

Dynamics of SARS-CoV-2 exposure in Malawian infants between February 2020 and May 2021.

Silvia Baroncelli, Clementina Maria Galluzzo, Stefano Orlando, Robert Mphwere, Thom Kavalo, Richard Luhanga, Roberta Amici, Marco Floridia, Mauro Andreotti, Paola Scarcella and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical virology plus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Silvia BaroncelliNational Center for Global Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Clementina Maria GalluzzoNational Center for Global Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Stefano OrlandoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
Robert MphwereDREAM Program, Community of S. Egidio, P.O. Box 30355, Blantyre, Malawi.
Thom KavaloDREAM Program, Community of S. Egidio, P.O. Box 30355, Blantyre, Malawi.
Richard LuhangaDREAM Program, Community of S. Egidio, P.O. Box 30355, Blantyre, Malawi.
Roberta AmiciNational Center for Global Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Marco FloridiaNational Center for Global Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Mauro AndreottiNational Center for Global Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Paola ScarcellaDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
Maria Cristina MarazziDepartment of Human Sciences, LUMSA University, Borgo S. Angelo 13, 00193 Rome, Italy.
Marina GiulianoNational Center for Global Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Istituto Superiore di Sanità · ITCommunity Living · USUniversity of Rome Tor Vergata · ITLibera Università Maria SS. Assunta · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Very limited information is available on SARS-CoV-2 seroprevalence in infants in sub-Saharan countries. Objective: In this study, we aimed to determine the rate and the temporal evolution of SARS CoV-2 seropositivity in breastfed Malawian infants. Study design: Blood samples ( Results: The confirmed prevalence of anti-SARS CoV-2 antibodies was 31.0% (95% CI: 23.7%-38.3%) with no significant difference between HIV-exposed and HIV-unexposed infants (29.3% and 37.1% respectively, Conclusions: Our data underline the wide spread of the SARS-CoV-2 infection in the pediatric population in sub-Saharan Africa. Design of more specific serological tests for African samples and improvements in serosurveillance programs are needed for more rigorous monitoring of the dynamics of SARS-CoV-2 infection in Africa.

Indexed as

infantsMalawiSARS-CoV-2 antibody prevalence

Identifiers

PMID36128323
PMCPMC9477783
OpenAlexW4296202787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.